Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months

Veradermics (NYSE: MANE) released topline results from an open-label Phase 2 trial of its VDPHL01 candidate in women with mild-to-moderate pattern hair loss. No efficacy/safety figures were provided in the excerpt, so the near-term read-through is limited.

Analysis

Veradermics (NYSE: MANE) released topline results from an open-label Phase 2 trial of its VDPHL01 candidate in women with mild-to-moderate pattern hair loss. No efficacy/safety figures were provided in the excerpt, so the near-term read-through is limited.